Q3 EPS Estimate for Phio Pharmaceuticals Lowered by Analyst

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) – Stock analysts at HC Wainwright decreased their Q3 2026 earnings estimates for shares of Phio Pharmaceuticals in a research report issued to clients and investors on Wednesday, August 26th. HC Wainwright analyst M. Keller now expects that the company will post earnings per share of ($0.37) for the quarter, down from their prior estimate of ($0.34). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.47) EPS and FY2027 earnings at ($0.77) EPS.

Phio Pharmaceuticals (NASDAQ:PHIO) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.36).

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $14.00.

Phio Pharmaceuticals Price Performance

NASDAQ:PHIO opened at $1.12 on Friday. The firm has a 50-day moving average of $1.05 and a two-hundred day moving average of $1.13. The stock has a market cap of $13.01 million, a P/E ratio of -0.87 and a beta of 0.82. Phio Pharmaceuticals has a 1-year low of $0.81 and a 1-year high of $4.19.

Institutional Trading of Phio Pharmaceuticals

An institutional investor recently raised its position in Phio Pharmaceuticals stock. Geode Capital Management LLC raised its stake in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 60.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 92,638 shares of the company’s stock after acquiring an additional 34,732 shares during the quarter. Geode Capital Management LLC owned approximately 0.86% of Phio Pharmaceuticals worth $97,000 at the end of the most recent quarter. Institutional investors and hedge funds own 57.31% of the company’s stock.

About Phio Pharmaceuticals

Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.